Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multip...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

Aldawg May. 6 at 7:06 PM

$BLRX This is fantastic. I only need this to jump up another $95 to break even. 🙃

2 · Reply

tankwfwf May. 6 at 4:28 PM

$BLRX 3.41 ÷ 40 = .08.........Phil is a liar and a thief...

0 · Reply

BlakeTaylor12 May. 6 at 4:05 PM

$BLRX def offering incoming lol

0 · Reply

BlakeTaylor12 May. 5 at 3:05 PM

$BLRX sorry forgot the link... i think the play for us will be to be acquired/licensed and then combod with them https://www.usnews.com/news/health-news/articles/2026-05-04/fda-green-lights-expanded-access-to-pancreatic-cancer-drug-daraxonrasib

0 · Reply

BlakeTaylor12 May. 5 at 4:03 AM

$BLRX I posted about this game changing drug in November. It fundamentally has changed our future and tam. Been doing significant research lately and it soar appears the best path forward for us to to combo wit them which lowers our tam and ultimately delays fda approval. Still significant upside potential from here IF we get positive data but we’re basically no longer a ” standalone “ drug

0 · Reply

BLRXlongRIPorYOLO May. 4 at 8:56 AM

$BLRX what ever happend to the Keytruda stuff?

1 · Reply

Rainman_3 May. 1 at 6:45 PM

$BLRX

0 · Reply

tankwfwf Apr. 29 at 8:58 PM

$BLRX offering on the horizon..

1 · Reply

yourfinancialteacher Apr. 29 at 5:28 PM

$BLRX bottom in?

2 · Reply

asromaforever Apr. 29 at 5:12 PM

$BLRX I am leaving this turd behind after 5 years. This was the biggest trading mistake of my life. Israeli scum.

0 · Reply

BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1

Tue, 28 Apr 2026 07:00:00 -0400 - 15 days ago

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

2026-04-08T10:50:48.000Z - 5 weeks ago

BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial

2026-04-08T09:26:21.000Z - 5 weeks ago

BioLineRx, Hemispherian initiate clinical trial of GLIX1

Wed, 08 Apr 2026 02:30:00 -0400 - 5 weeks ago

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma

2026-03-26T11:08:04.000Z - 6 weeks ago

BioLineRx initiates Phase 1/2a study of GLIX1

Thu, 26 Mar 2026 07:00:00 -0400 - 6 weeks ago

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Mar 23, 2026, 8:30 AM EDT - 7 weeks ago

BioLineRx Earnings Call Transcript: Q4 2025

2026-03-23T12:06:18.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 23, 2026

LAR MBX

2026-03-23T11:11:27.000Z - 7 weeks ago

Earnings Scheduled For March 23, 2026

2026-03-23T11:10:51.000Z - 7 weeks ago

BioLineRx provides corporate update

Mon, 23 Mar 2026 07:00:00 -0400 - 7 weeks ago

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

2026-03-23T00:55:17.000Z - 7 weeks ago

BioLineRx (BLRX) and Others Set to Announce Earnings

Mon, 16 Mar 2026 07:00:00 -0400 - 2 months ago

BioLineRx to Report 2025 Annual Results on March 23, 2026

Nov 24, 2025, 8:30 AM EST - 6 months ago

BioLineRx Earnings Call Transcript: Q3 2025

2025-11-24T13:01:39.000Z - 6 months ago

BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall

2025-11-24T12:34:08.000Z - 6 months ago

BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture

2025-11-24T12:05:22.000Z - 6 months ago

Options Volatility and Implied Earnings Moves Today, November 24, 2025

A BLBD FLNC KEYS LX PFLT SMTC

2025-11-24T12:05:10.000Z - 6 months ago

BioLineRx reports Q3 EPS 0c vs 0c last year

Mon, 24 Nov 2025 07:00:00 -0500 - 6 months ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-24T11:11:10.000Z - 6 months ago

Earnings Scheduled For November 24, 2025

2025-11-21T15:01:37.000Z - 6 months ago

BioLine Rx's Earnings: A Preview

Tue, 18 Nov 2025 07:00:00 -0500 - 6 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Mon, 17 Nov 2025 07:00:00 -0500 - 6 months ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

2025-09-29T12:33:46.000Z - 8 months ago

BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy

Sep 29, 2025, 8:30 AM EDT - 8 months ago

BioLineRx Transcript: Study Update

2025-09-29T11:10:48.000Z - 8 months ago

BioLineRx, Hemispherian AS establish joint venture to develop GLIX1

Mon, 29 Sep 2025 07:00:00 -0400 - 8 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Aug 14, 2025, 8:30 AM EDT - 9 months ago

BioLineRx Earnings Call Transcript: Q2 2025

2025-08-14T11:05:57.000Z - 9 months ago

BioLineRx reports Q2 EPS 0c vs. 0c last year

2025-08-14T11:05:16.000Z - 9 months ago

Options Volatility and Implied Earnings Moves Today, August 14, 2025

AMAT BTBT CSCO DE JD KULR NTES

Thu, 14 Aug 2025 07:00:00 -0400 - 9 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-08-14T08:32:32.000Z - 9 months ago

Earnings Scheduled For August 14, 2025

Thu, 07 Aug 2025 07:00:00 -0400 - 9 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Fri, 30 May 2025 13:58:03 -0400 - 1 year ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

2025-05-30T12:46:29.000Z - 1 year ago

BioLineRx upgraded to Buy from Hold at JonesResearch

2025-05-30T11:05:10.000Z - 1 year ago

BioLineRx announces new data from Phase 2 combination trial of motixafortide

Fri, 30 May 2025 07:00:00 -0400 - 1 year ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q1 2025

2025-05-27T11:05:36.000Z - 1 year ago

BioLineRx reports Q1 EPS 0c vs. 0c last year

2025-05-27T11:05:32.000Z - 1 year ago

Options Volatility and Implied Earnings Moves Today, May 27, 2025

AZO BNS BOX GLNG OKTA PDD SHIP

Tue, 27 May 2025 07:00:00 -0400 - 1 year ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

2025-05-27T08:32:09.000Z - 1 year ago

Earnings Scheduled For May 27, 2025

2025-05-26T14:01:50.000Z - 1 year ago

A Look at BioLine Rx's Upcoming Earnings Report

Tue, 20 May 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

2025-04-01T20:36:11.000Z - 1 year ago

BioLineRx downgraded to Hold from Buy at JonesResearch

Mar 31, 2025, 8:30 AM EDT - 1 year ago

BioLineRx Earnings Call Transcript: Q4 2024

Mon, 31 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

2025-03-28T16:01:40.000Z - 1 year ago

Uncovering Potential: BioLine Rx's Earnings Preview

Mon, 24 Mar 2025 07:00:00 -0400 - 1 year ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 2 years ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 2 years ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Nov 20, 2023, 7:00 AM EST - 2 years ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

Nov 13, 2023, 7:00 AM EST - 2 years ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Oct 31, 2023, 9:00 AM EDT - 2 years ago

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Oct 12, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

Sep 28, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

Sep 11, 2023, 7:00 AM EDT - 2 years ago

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

Aldawg May. 6 at 7:06 PM

$BLRX This is fantastic. I only need this to jump up another $95 to break even. 🙃

2 · Reply

tankwfwf May. 6 at 4:28 PM

$BLRX 3.41 ÷ 40 = .08.........Phil is a liar and a thief...

0 · Reply

BlakeTaylor12 May. 6 at 4:05 PM

$BLRX def offering incoming lol

0 · Reply

BlakeTaylor12 May. 5 at 3:05 PM

0 · Reply

BlakeTaylor12 May. 5 at 4:03 AM

0 · Reply

BLRXlongRIPorYOLO May. 4 at 8:56 AM

$BLRX what ever happend to the Keytruda stuff?

1 · Reply

Rainman_3 May. 1 at 6:45 PM

$BLRX

0 · Reply

tankwfwf Apr. 29 at 8:58 PM

$BLRX offering on the horizon..

1 · Reply

yourfinancialteacher Apr. 29 at 5:28 PM

$BLRX bottom in?

2 · Reply

asromaforever Apr. 29 at 5:12 PM

$BLRX I am leaving this turd behind after 5 years. This was the biggest trading mistake of my life. Israeli scum.

0 · Reply

Goyl Apr. 29 at 4:37 PM

$BLRX my last post here .. It was wonderful running with you all, now or soon my journey here ends, Wishing you all great success.. even shorts.. but heed this.. cover cover cover …

0 · Reply

MarketMasterMind Apr. 28 at 6:20 PM

$RPGL | $POLA | $BLRX | $AUUD 🤑Ⓜ️

1 · Reply

prismmarketview Apr. 28 at 4:46 PM

PRISM Mid-Day Movers: Consumer Products and MedTech are Today's Leaders. Shares of Sleep Number Corporation (Nasdaq: $SNBR) are surging, with the stock up about 45% bioAffinity Technologies, Inc. (NASDAQ: $BIAF) is putting in a strong session, with shares up roughly 22% Other Notable Movers: BioLineRx Ltd. ( $BLRX) up 13% PDS Biotechnology Corp ( $PDSB) up 11% IO Biotech ( $IOBT) down -27% https://prismmarketview.com/prism-mid-day-movers-consumer-products-and-medtech-are-todays-leaders/

0 · Reply

StocktwitsNews Apr. 28 at 12:18 PM

BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months $BLRX https://stocktwits.com/news/equity/markets/blrx-stock-surges-pre-market-on-cancer-trial-catalyst-eyes-50-dma-breakout-for-first-time-in-nearly-2-months/cZB8vB4Re56

1 · Reply

DARKP00L Apr. 28 at 11:31 AM

$BLRX 07:13 on Apr. 28 2026 BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas #tradeideas

0 · Reply

Rainman_3 Apr. 28 at 11:20 AM

$BLRX

0 · Reply

TwongStocks Apr. 28 at 11:02 AM

$BLRX BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302755515.html • Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center • Data from the Phase 1 part of the study anticipated in H1 2027

0 · Reply

TwongStocks Apr. 21 at 2:44 PM

$BLRX Their partner, Hemispheran, is publishing two GLIX1 abstracts at the 2026 ASCO Annual Meeting. GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity https://www.asco.org/abstracts-presentations/259219/abstract Synergistic antitumor activity of GLIX1, a small molecule TET2 activator, in combination with PARP inhibition across multiple cancers https://www.asco.org/abstracts-presentations/263530 Both abstract texts will be available on May 21 at 05:00 PM EST.

0 · Reply

JoNCherry Apr. 17 at 9:57 PM

$BLRX watching closely next week

0 · Reply

JoNCherry Apr. 17 at 1:57 AM

$BLRX not sure when they will release the data

1 · Reply

JoNCherry Apr. 17 at 1:57 AM

$BLRX

0 · Reply

Goyl Apr. 16 at 4:49 PM

$BLRX 👀 beastmodecoming🦍 $2.50+ !!! Watchlearn $$ 🎯 $18.99 Started position in $RUM 🍹 Adding $VSTM on dips

0 · Reply

Market Cap	12.97M
Revenue (ttm)	1.18M
Net Income (ttm)	-1.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-100.00%
Debt to Equity Ratio	0.38

Volume	22,600
Avg Vol	19,942
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	60%
Beta	1.42
Analysts	Strong Sell
Price Target	$20.33